Claims for Patent: 5,681,818

Summary for Patent: 5,681,818

Title:	Therapeutic uses of human somatomedin carrier proteins
Abstract:	This invention relates to polypeptides that are human somatomedin carrier protein subunits and to processes for producing them. The carrier protein subunits bind to human somatomedin-like polypeptides, also known as insulin-like growth factors. The process involves preparation from a human serum fraction, Cohn IV-1, by a molecule of various chromatographic steps. This invention also relates to DNA molecules encoding human somatomedin carrier protein-like polypeptides, recombinant DNA molecules, hosts, processes for producing carrier protein-like polypeptides, human somatomedin carrier protein-like polypeptides produced using those molecules, hosts and processes. The invention relates to DNA molecules and their expression in appropriate hosts. The recombinant DNA molecules contain DNA molecules that code for polypeptides which have a biological activity of the human carrier protein or a human carrier protein subunit capable of binding somatomedins. The DNA molecules, recombinant DNA molecules, hosts, and processes of this invention may be used in the production of polypeptides useful in a variety of therapeutic, diagnostic, and other useful applications.
Inventor(s):	Spencer; Emerald Martin (San Francisco, CA), Talkington-Verser; Carol (San Rafael, CA)
Assignee:	Celtrix Pharmaceuticals, Inc. (Santa Clara, CA)
Application Number:	08/320,123
Patent Claims:	1. A method for inhibiting the growth of somatomedin-dependent cancer, for inhibiting the effect of somatomedin-C in acromegaly, for inhibiting the growth of retinal blood vessels and fibrous tissues in diabetic retinopathy, for inhibiting the growth of keloid sears, or for inhibiting the growth of tissue in the orbit of the eyes in malignant exophthalmos, comprising administering an effective amount of a composition comprising a carrier protein-like polypeptide capable of binding somatomedin-like polypeptides said polypeptide having an amino acid sequence selected from the group consisting of amino acids 27 through 290 of FIG. 4, amino acids 27 through 290 of FIG. 4 having a methionine residue preceding amino acid 27, and naturally occurring allelic variants thereof, and a pharmacologically acceptable carrier. 2. The method of claim 1 wherein the naturally occurring variant has an Alanine at amino acid position 5. 3. The method of claim 1 wherein said carrier protein-like polypeptide capable of binding somatomedin-like peptides has the sequence of amino acids 27 through 290 of FIG. 4 or amino acids 27 through 290 of FIG. 4 having a methionine residue preceding amino acid 27. 4. A method for treating osteoporosis in humans comprising administering an effective amount of a composition comprising a carrier protein-like polypeptide capable of binding somatomedin-like polypeptides said polypeptide having an amino acid sequence selected from the group consisting of amino acids 27 through 290 of FIG. 4, amino acids 27 through 290 of FIG. 4 having a methionine residue preceding amino acid 27, and naturally occurring allelic variants thereof and wherein said polypeptide is substantially complexed with at least one human somatomedin-like polypeptide and a pharmaceutically acceptable carrier. 5. The method of claim 4 wherein said carrier protein-like polypeptide capable of binding somatomedin-like peptides has the sequence of amino acids 27 through 290 of FIG. 4 or amino acids 27 through 290 of FIG. 4 having a methionine residue preceding amino acid 27. 6. The method of claim 4 wherein said carrier protein-like polypeptide capable of binding somatomedin-like peptides has the sequence of amino acids 27 through 290 of FIG. 4. 7. The method of claim 4 wherein said naturally occurring variant has an amino terminal amino acid sequence of Gly-Ala-Ser-Ser-Gly- or Met-Gly-Ala-Ser-Ser-Gly. 8. A method for stimulating the healing of human and other animal wounds comprising administering an effective amount of a composition comprising a carrier protein-like polypeptide capable of binding somatomedin-like peptides said polypeptide having an amino acid sequence selected from the group consisting of amino acids 27 through 290 of FIG. 4, amino acids 27 through 290 of FIG. 4 having a methionine residue preceding amino acid 27, and naturally occurring allelic variants thereof and a pharmaceutically acceptable carrier and wherein said polypeptide is substantially complexed with at least one human somatomedin-like polypeptide. 9. The method of claim 8 wherein said carrier protein-like polypeptide capable of binding somatomedin-like peptides has the sequence of amino acids 27 through 290 of FIG. 4 or amino acids 27 through 290 of FIG. 4 having a methionine residue preceding amino acid 27. 10. The method of claim 8 wherein said naturally occurring variant has an amino terminal amino acid sequence of Gly-Ala-Ser-Ser-Gly- or Met-Gly-Ala-Ser-Ser-Gly-. 11. A method for stimulating growth of bone comprising administering an effective mount of a composition comprising a carrier protein-like polypeptide capable of binding somatomedin-like peptides said polypeptide having an amino acid sequence selected from the group consisting of amino acids 27-290 of FIG. 4, amino acids 27-290 of FIG. 4 having a methionine residue preceding amino acid 27, and naturally occurring allelic variants thereof and wherein said polypeptide is substantially complexed with at least one human somatomedin-like polypeptide and a pharmaceutically acceptable carrier. 12. The method of claim 11 wherein said carrier protein-like polypeptide capable of binding somatomedin-like peptides has the sequence of amino acids 27 through 290 of FIG. 4 or amino acids 27 through 290 of FIG. 4 having a methionine residue preceding amino acid 27. 13. The method of claim 11 wherein said naturally occurring variant has an amino terminal amino acid sequence of Gly-Ala-Ser-Ser-Gly- or Met-Gly-Ala-Ser-Ser-Gly-. 14. A method for stimulating animal growth comprising administering an effective amount of a composition comprising a carrier protein-like polypeptide capable of binding somatomedin-like peptides said polypeptide having an amino acid sequence selected from the group consisting of amino acids 27-290 of FIG. 4, amino acids 27-290 of FIG. 4 having a methionine residue preceding amino acid 27, and naturally occurring allelic variants thereof and wherein said polypeptide is substantially complexed with at least one human somatomedin-like polypeptide and a pharmaceutically acceptable carrier. 15. The method of claim 14 wherein said carrier protein-like polypeptide capable of binding somatomedin-like peptides has the sequence of amino acids 27 through 290 of FIG. 4 or amino acids 27 through 290 of FIG. 4 having a methionine residue preceding amino acid 27. 16. The method of claim 14 wherein said naturally occurring variant has an amino terminal amino acid sequence of Gly-Ala-Ser-Ser-Gly- or Met-Gly-Ala-Ser-Ser-Gly-.